Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
−0.68 EUR
−34.01 M EUR
0.00 EUR
57.82 M
About Aldeyra Therapeutics, Inc.
Sector
Industry
CEO
Todd C. Brady
Website
Headquarters
Lexington
Founded
2004
FIGI
BBG006BGMQZ8
Aldeyra Therapeutics, Inc. is a biotechnology company, which engages in research and development activities with related general business planning, including raising capital. It engages in the discovery of therapies designed to treat immune-mediated diseases. The company was founded by Thomas A. Jordan and John E. Dowling on August 13, 2004 and is headquartered in Lexington, MA.
An aggregate view of professional's ratings.
Displays a symbol's price movements over previous years to identify recurring trends.
Frequently Asked Questions
The current price of 137 is 4.57 EUR — it has decreased by −2.16% in the past 24 hours. Watch ALDEYRA THERAPEUTICS INC stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on GETTEX exchange ALDEYRA THERAPEUTICS INC stocks are traded under the ticker 137.
137 stock has fallen by −0.59% compared to the previous week, the month change is a 0.48% rise, over the last year ALDEYRA THERAPEUTICS INC has showed a 45.48% increase.
We've gathered analysts' opinions on ALDEYRA THERAPEUTICS INC future price: according to them, 137 price has a max estimate of 11.52 EUR and a min estimate of 7.68 EUR. Watch 137 chart and read a more detailed ALDEYRA THERAPEUTICS INC stock forecast: see what analysts think of ALDEYRA THERAPEUTICS INC and suggest that you do with its stocks.
137 stock is 2.82% volatile and has beta coefficient of 0.85. Track ALDEYRA THERAPEUTICS INC stock price on the chart and check out the list of the most volatile stocks — is ALDEYRA THERAPEUTICS INC there?
Today ALDEYRA THERAPEUTICS INC has the market capitalization of 274.25 M, it has decreased by −0.72% over the last week.
Yes, you can track ALDEYRA THERAPEUTICS INC financials in yearly and quarterly reports right on TradingView.
ALDEYRA THERAPEUTICS INC is going to release the next earnings report on Mar 6, 2025. Keep track of upcoming events with our Earnings Calendar.
137 earnings for the last quarter are −0.22 EUR per share, whereas the estimation was −0.22 EUR resulting in a −1.16% surprise. The estimated earnings for the next quarter are −0.23 EUR per share. See more details about ALDEYRA THERAPEUTICS INC earnings.
ALDEYRA THERAPEUTICS INC revenue for the last quarter amounts to 0.00 EUR, despite the estimated figure of 0.00 EUR. In the next quarter, revenue is expected to reach 19.04 M EUR.
137 net income for the last quarter is −13.57 M EUR, while the quarter before that showed −15.73 M EUR of net income which accounts for 13.70% change. Track more ALDEYRA THERAPEUTICS INC financial stats to get the full picture.
No, 137 doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Dec 25, 2024, the company has 10.00 employees. See our rating of the largest employees — is ALDEYRA THERAPEUTICS INC on this list?
Like other stocks, 137 shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade ALDEYRA THERAPEUTICS INC stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So ALDEYRA THERAPEUTICS INC technincal analysis shows the sell today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating ALDEYRA THERAPEUTICS INC stock shows the sell signal. See more of ALDEYRA THERAPEUTICS INC technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.